Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 26;218(6):e20201329. doi: 10.1084/jem.20201329

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Amgen Inc

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 10. — Antitumor activity of targeting CCR8 expression on tumor-infiltrating T reg cells. (A) CT26 tumor growth curves of animals treated with CCR8-specific depleting and nondepleting antibodies, along with depleting and nondepleting isotype controls (top). (B and C) Averaged tumor growth (B) and overall survival of animals (C) treated as in A. (D) Averaged tumor growth curves of MC38 tumors treated with isotype control, anti-CCR8, anti–PD-1, or combination. (E) Overall survival of MC38 tumor bearing mice treated in D. (F) Averaged tumor growth curves of B16F10 tumors treated with Isotype control, anti-CCR8, anti–PD-1, or combination. (G) Overall survival of B16F10 tumor-bearing mice treated in F (****, P < 0.0001; ***, P < 0.0002; **, P < 0.002; *, P < 0.05; two-way ANOVA with Tukey’s post-hoc for tumor growth inhibition and Mantel-Cox log rank test for survival curve analysis).